HDR Monotherapy for Prostate Cancer: A Feasibility Study of Focal Radiation Therapy Yields
Brachytherapy as a monotherapy treatment is highly effective for localized prostate cancer,
traditionally being delivered to the whole prostate gland. Lately, low dose rate (LDR)
brachytherapy has been increasingly replaced by high dose rate (HDR) brachytherapy treatment
schemes. While brachytherapy's oncologic outcomes are excellent, it is not without incidence
adverse effects including urinary, rectal, and sexual toxicities that affect the patient's
quality of life.
This study will incorporate HDR monotherapy treatment option for early stages and favourable
risk prostate cancer.
Additionally, we aim to evaluate the role of focal HDR brachytherapy for well-defined
disease based on multiparametric MRI (mpMRI). This approach may offer an option of reducing
the treatment toxicities while maintaining oncologic outcomes when compared with whole-gland
therapy. Advantages in quality of life could be exhibited in the form of reduced urinary
discomfort and incontinence, rectal symptoms, and improved erectile and prostatic gland
function. This study would be particularly relevant in the current era of earlier localized
prostate cancer detection, where newer imaging modalities (e.g. mpMRI) become a routine
component of patient care.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society